as well as antibodies isolated from humans who had recovered from COVID-19. Scientists from Regeneron selected the two most potent, non-competing virus-neutralising antibodies and scaled up ...

Regeneron is already working on ramping ... It is being tested in phase 2/3 trials both as a treatment for coronavirus infections as well as prophylaxis against infection in people exposed to ...

Pembrolizumab is a checkpoint inhibitor that binds to the protein PD-1 on T cells to help them recognize and attack invaders.

Regeneron settles patent lawsuit over protein for testing COVID-19 treatments December 16, 2024 AnaptysBio will end the development of its experimental drug to treat eczema as the treatment failed ...